Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Preston Dunnmon"'
Autor:
Bang Wang, Dali Zhou, Jialu Zhang, Yoonhee Kim, Ling-Wan Chen, Preston Dunnmon, Steven Bai, Ququan Liu, Eiji Ishida
Publikováno v:
Contemporary clinical trials.
In cardiovascular outcome trials, the win ratio (WR) method models the composite endpoint under a hierarchical structure to account for clinical priorities. It also can be applied to both survival and nonsurvival outcomes.In this article, we assess t
Autor:
Mathew S. Maurer, Preston Dunnmon, Mariana Fontana, Cristina Candida Quarta, Krishna Prasad, Ronald M. Witteles, Claudio Rapezzi, James Signorovitch, Isabelle Lousada, Giampaolo Merlini
Publikováno v:
Circulation: Heart Failure. 15
Immunoglobulin light chain amyloidosis is a rare, multisystemic, phenotypically heterogenous disease affecting cardiovascular, renal, neurological, and gastrointestinal systems to varying degrees. Its underlying cause is a plasma cell dyscrasia chara
Autor:
Richard Clark, Paul D. Ziegler, Norman Stockbridge, Fraz A. Ismat, Mintu P. Turakhia, Suneet Mittal, Preston Dunnmon, Robert Kleiman, Peter R. Kowey, James A. Reiffel, Jonathan P. Piccini, Philip T. Sager
Publikováno v:
American Heart Journal. 187:156-169
This white paper, prepared by members of the Cardiac Safety Research Consortium (CSRC), discusses important issues regarding scientific and clinical aspects of long-term electrocardiographic safety monitoring during clinical drug development. To prom
Autor:
Bertram Pitt, Scott D. Solomon, Javed Butler, Mihai Gheorghiade, Vasiliki V. Georgiopoulou, Christopher M. O'Connor, Lothar Roessig, Clyde W. Yancy, Robert J. Cody, Martin Lefkowitz, Erik B. Schelbert, Norman Stockbridge, Stephen Grant, Monica R. Shah, Robert O. Bonow, So Young Kim, Mona Fiuzat, Stuart Kupfer, Gregg C. Fonarow, Frank Misselwitz, Preston Dunnmon, Robert J. Mentz, Sean P. Collins, Kirkwood F. Adams, Wilfried Dinh
Publikováno v:
American Heart Journal. 169:305-314
Advances in medical therapies leading to improved patient outcomes are in large part related to successful conduct of clinical trials that offer critical information regarding the efficacy and safety of novel interventions. The conduct of clinical tr
Autor:
Gerasimos Filippatos, Christopher M. O'Connor, Norman Stockbridge, John R. Teerlink, Lothar Roessig, Mihai Gheorghiade, Marc A. Pfeffer, Carolyn S.P. Lam, John G.F. Cleland, Bertram Pitt, Giuseppe M.C. Rosano, Ovidiu Chioncel, Frank Misselwitz, Catherine N. Marti, Scott D. Solomon, Martin Lefkowitz, Michael R. Zile, Ali Ahmed, Preston Dunnmon, Robert J. Cody, Erik B. Schelbert, Vasiliki V. Georgiopoulou, Hani N. Sabbah, Michele Senni, Robert O. Bonow, John J.V. McMurray, Burkert Pieske, Gregg C. Fonarow, Savina Nodari, Sanjiv J. Shah, Javed Butler, Sean P. Collins
Publikováno v:
JACC: Heart Failure. 2:97-112
The burden of heart failure with preserved ejection fraction (HFpEF) is considerable and is projected to worsen. To date, there are no approved therapies available for reducing mortality or hospitalizations for these patients. The pathophysiology of
Autor:
Michael R. Zile, Patrice Desvigne-Nickens, Michele Senni, Andrew Hamer, Sarit Rotman, Richard L. Clark, Patricia Kay-Mugford, Stefan D. Anker, Juan Maya, Harold S. Bernstein, Wilfried Dinh, Christophe Depre, Kelly S Lewis, Javed Butler, Pia S. Pollack, Frank Kramer, James E. Udelson, Bertram Pitt, Mahesh J. Patel, Sanjiv J. Shah, Simon Maybaum, Preston Dunnmon, Afshin Salsali, Martin Lefkowitz, Jason Sims, Carine E. Hamo, Norman Stockbridge, Mihai Gheorghiade, Giuseppe M.C. Rosano, Clyde W. Yancy, Lothar Roessig
Publikováno v:
Circulation. Heart failure. 9(11)
The epidemiological, clinical, and societal implications of the heart failure (HF) epidemic cannot be overemphasized. Approximately half of all HF patients have HF with preserved ejection fraction (HFpEF). HFpEF is largely a syndrome of the elderly,
Autor:
Stephen J. Greene, Hani N. Sabbah, Wilson S. Colucci, Frank Kramer, Christopher J. Larson, Raymond J. Kim, Javed Butler, Ramin V. Parsey, Mihai Gheorghiade, Lawrence I. Deckelbaum, James C. Carr, Michele Senni, Wilfried Dinh, Sanjiv J. Shah, Preston Dunnmon, John G.F. Cleland, Thomas Krahn, Shunichiro Okada, David Crandall, Norman Stockbridge, Stephen E. Epstein, Sergey Sikora, Karin Wåhlander
Publikováno v:
Circulation: Heart Failure. 9
Compared with heart failure (HF) care 20 to 30 years ago, there has been tremendous advancement in therapy for ambulatory HF with reduced ejection fraction with the use of agents that block maladaptive neurohormonal pathways. However, during the past
Autor:
Peter R. Kowey, Paul Dorian, Craig M. Pratt, Stefan H. Hohnloser, Jose Brum, Preston Dunnmon, Hussein R. Al-Khalidi, Michael J. Holroyde
Publikováno v:
Journal of the American College of Cardiology. 52(13):1076-1083
ObjectivesThe goal of this study was to determine whether azimilide, as compared with placebo, will reduce the number of emergency department (ED) visits and hospitalizations caused by arrhythmias or cardiac events in patients with an implantable car
Autor:
Muthiah Vaduganathan, Matthew E. Harinstein, Sean P. Collins, Gregg C. Fonarow, Mona Fiuzat, Stephen J. Greene, Robert J. Mentz, John J.V. McMurray, Javed Butler, Norman Stockbridge, Mihai Gheorghiade, Robert O. Bonow, Marc A. Pfeffer, Christopher M. O'Connor, Giuseppe M.C. Rosano, Clyde W. Yancy, Preston Dunnmon, Frank Misselwitz, Scott D. Solomon, Mandeep R. Mehra, Wilfried Dinh
There are more than 1 million primary hospitalizations for heart failure ( HF ) annually in the USA alone, and post-discharge outcomes remain persistently poor despite available therapies and quality improvement initiatives. Recent international rand
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86abf206f6d3cb8521039853de9c69f7
https://acuresearchbank.acu.edu.au/item/8q95x/site-selection-for-heart-failure-clinical-trials-in-the-usa
https://acuresearchbank.acu.edu.au/item/8q95x/site-selection-for-heart-failure-clinical-trials-in-the-usa
Autor:
Carolyn S.P. Lam, Sean P. Collins, Preston Dunnmon, Wilfried Dinh, Ovidiu Chioncel, Muthiah Vaduganathan, Mihai Gheorghiade, Lothar Roessig, Giuseppe M.C. Rosano, Ami N. Shah, Gregg C. Fonarow, Naoki Sato, Javed Butler, Andrew P. Ambrosy, Robert J. Mentz, Stephen J. Greene, Burkert Pieske, Stefan D. Anker
Publikováno v:
American heart journal, vol 168, iss 2
Recent international phase III clinical trials of novel therapies for hospitalized heart failure (HHF) have failed to improve the unacceptably high postdischarge event rate. These large studies have demonstrated notable geographic and site-specific v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15da26120eea00b1f71ac55bb236f442
https://escholarship.org/uc/item/8qf1n3r6
https://escholarship.org/uc/item/8qf1n3r6